AMENDMENTS

IN THE CLAIMS

1.   (currently amended) A method ~~of formulating a composition for preventing epithelial ovarian cancer for administration to a human female subject comprising selecting an agent based on its ability to upregulate TGF-β expression in the ovarian epithelium by testing said agent by treating ovarian epithelial cells through exposure to said agent and determining the resulting expression of TGF-β in the treated ovarian epithelial cells.~~ for determining the effectiveness of an agent for preventing epithelial ovarian cancer in a human female, based upon the ability of said agent to upregulate TGF-β in ovarian epithelium, said method comprising the steps of:

(a) exposing said agent to ovarian epithelial cells;

(b) measuring the resulting expression of TGF-β in the exposed ovarian epithelial cells; and

(c) determining the agent to be effective for the prevention of epithelial ovarian cancer in a human female when said measuring step indicates an upregulation of TGF-β in said ovarian epithelial cells.

2. (previously presented)   The method of claim 1 wherein said agent is a progestin product.

3. (previously presented)   The method of claim 2 wherein said ovarian epithelial cells are treated with said agent using an *in vivo* test.

4. (previously presented)   The method of claim 2 wherein said test is conducted *in vitro*.

2

Serial No.: 09/528,963   File No.: 31162X

5. (previously presented)   The method of claim 2 wherein said measured TGF-β expression is upregulation of TGF-β 2 or TGF-β 3.

6. (canceled)

3